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effectweness estimating by continuous 12.lead electrocardiographic analysis (12L-ECG). 
Methods: Out of 157 consecutive pts who presented in the first 6 hours of STEMI were 
studied The course of higher ST-segment elevation was evaluated by continuous lZL- 
ECG monitoring. Successful IT was considered as the abrupt 50% ST stable recovery in 
the first 90 mnts after IT Initiation. The studied markers were estimated upon admission. 
Results: Seventy-nine patients had positive (>O.lng/L) cTnl. There was a significant 
relationship between cTnl and prehospital delay (time interval from Index pam to admis- 
sion)(Spearman R=OSl; p<O.OOl) Patients wth or without positive cTnl didn’t differ in 
either hs-CRP (0.58mg/dl vs.O.Mmg/dl respectively; p=O.65), Lp(a) (25.7mg/dl 
vs.26.3mg/dl respectwely; p=O.74), or Fb (3.4glL vs.3.3g/L respectively; p=O.85). In the 
first 90 mm 85 (851157; 54.1%) patients had attained 50% ST recovery. By univariate 
logistic wgrewon analysis cTnl (RR=0.44, p=O.OOl), time interval from index pain to 
thrombolysis Initiation (R&0.88; pcO.OOl), hs-CRP (R&0.74; pcO.OOl), and diabetes 
mellitus (RR=0.27; p=O.OOl) were related to IT effectiveness. Fb or Lp(a) were not (p=NS 
for both). By multivanate analysis time Interval from index pain to IT initiation (R&0.54; 
pcO.001). hs-CRP (R&0.66; p=O.Ol), and diabetes mellitus (RR=0.30; p=O.OOS) were 
the only independent predictors of IT outcome. 
N: Total number of patients in each group; n: number of events; HR: hazard ratio; Cl: 
confidence interval; *Primary efficacy endpoint of ASSENT-3: 30.day mortality + in- 
hospital myocardial reinfarction + in-hospital refractory ischemia. 
1191-49 Impact of Multivessel Disease on Recovery of Left 
Ventricular Function After Primary Angioplasty for 
Acute Myocardial Infarction 
Jan-Henk E. Dambrink Rene J. van der Schaaf, Jan C. Hoorntje, Stoffer Reiffers, 
Arnoud W. van ‘t Hof. Harrv Survapranata. MenkoJan de Boer. Felix Ziilstra. lsala 
Klinieken, locatie Weezenlande~, .&.&a, The Netherlands ’ 
Conclusions: The present study implies that hs-CRP is a strong predictors of IT effec- 
tiveness whilst elevated plasma cTnl values may reflect the preceding myocardial macro- 
sis (strong asswatlon with prehospital delay). Fb and Lp(a) are not associated with 
thrombolysis outcome. Acute inflammatory reaction at the culprit artery may be responsi- 
ble for the fail of IT in pts wth high CRP. 
Background. In most patients (pts) with acute myocardial infarction (Ml), there IS consid- 
erable improvement of left ventricular function (LVF) after primary angioplasty (PA), pre- 
sumably by recovery of stunned myocardium. However, the impact of multivessel 
disease (MVD) on this process is largely unknown. 
Methods. To determine the impact of MVD and other clinical variables on the recovery of 
LVF we reviewed the data of 1702 pts with acute MI treated with PA. Pts were catego- 
rized in one- two- or three vessel disease (I-. 2., 3.VD) based on the angiogram before 
PA. Radionuclide ejection fraction (EF) was assessed before discharge and after 6 
months. 
1191-48 Outcome After Urgent Percutaneous Coronary 
Interventions in ASSENT-3 
Christophe Dubols. Ann Belmans, Chris Granger, Lars Wallentin, Paul W. Armstrong, 
Frans J. Van de Wed, for the ASSENT-3 Investigators, University Hospitals Leuven. 
Leuven. Belgium 
Background: When compared with unfractionated heparin (UFH). co-therapy with enox- 
apar~n (ENOX) or abciximab (ABC) results in a reduction of ischemic complications after 
ST-elevation acute myocardlal infarctnon treated with tenecteplase (ASSENT-3; n=8095). 
The effect of these new co-theraples on outcome after urgent percutaneous coronary 
interventions (PCI) is not known. Methods: Clinical outcomes after urgent PCI in the 
ASSENT-3 trial (n=716, 11.7%) were compared using Cox regression analysis including 
propensity scores and the timing of the event. Results: Results are shown in Table 1. 
Fewer ENOX and ABC treated patients needed urgent PCI compared with UFH (242/ 
2037 (11.9%) and 182/2009 (9.1%) vs. 292/2035 (14.3%); pcO.0001). Incidence of 
ischemlc events after urgent PCI was low and no significant differences between the 
treatments were seen, although there was a trend towards worse outcome with ABC. 
The incidence of non-cerebral major bleeding complications was significantly higher in 
the ABC arm compared with the UFH arm, while there was a modest increase with 
ENOX. Although total puncture-related bleeding rates were amilar, more major ones 
were seen with ENOX. The use of additional UFH during PCI was similar in the 3 groups 
(88% for ENOX, 71% for ABC and 71% for UFH). Conclusions: Although fewer patients 
needed urgent PCI after co-therapy with ABC and ENOX, clinical outcomes were less 
favorable I” this selected population, especially with ABC. 
Results. Serial EF was awlable in 575 pts: 278 pts (48%) had I-VD, 164 pts (28%) 2- 
VD and 133 (23%) 3-VD. 
Pts with MVD were older (age 56+11, 80*11 and 64+10 yrs in 1- 2- and 3.VD, respec- 
tively, pc.001) and more often had previous MI (5% 11% and 23%, pc.001). Anterior MI 
was less frequent in MVD (53%, 43% and 39%, p=.O22). There was no significant differ- 
ence in the prevalence of diabetes (8%. 10% and 8%, p=.298) or procedural wccess 
(96%, 96% and 92%. ~~202). 
Improvement of EF between discharge and 6 months decreased with more extensive 
coronary artery disease (CAD)(table). 
After correction for age, diabetes, previous Ml, infarct size and location, the extent of 
CAD remained a significant adverse predictor of recovery of LVF. 
Conclusion. Recovery of LVF after PA is impaired by more extensive CAD. This effect 
appears independent of other well known determinants of LVF after MI. 
EF before discharge and after 6 months in pts wth MVD 
EF predischarge (%) 
EF 6 months (%) 
Difference(%) 
Rel. difference(%) 
1 VD 
44*11 
48+10 
3.7*7.3 
11*21 
2VD 
45rll 
47*11 
1.8i7.6 
6+22 
3VD 
43ill 
44*12 
0.7~7.2 
3+20 
p-value 
0.480 
0.001 
< 0.001 
0.001 
1191-50 Patency of Infarct Related Artery Influences In-Hospital 
Outcome of Patients Undergoing Facilitated 
Endpunt 
Death at 30 days 
Remfarction 
Refractory lschemta 
Composite efficacy 
endpoint * 
Major bleeds 
Bleeds at arterial 
puncture site 
Major bleeds at arterial 
puncture site 
Label 
ENOX vs. 
UFH 
ABC vs. 
UFH 
ENOX vs. 
UFH 
ABC “s. 
UFH 
ENOX vs. 
UFH 
ABC vs. 
UFH 
ENOX vs. 
UFH 
ABC vs. 
UFH 
ENOX vs. 
UFH 
ABC vs. 
UFH 
ENOX vs. 
UFH 
ABC vs. 
UFH 
ENOX vs. 
UFH 
ABC vs. 
UFH 
Table I 
n/N (%) HR (95% Cl); 
P-value 
13/242 (5.37%) vs. 13/ 1.11 (0.51. 
292 (4.45%) 2.42); 0.80 
15/182 (8.24%) vs. 131 1.85 (0.87- 
292 (4.45%) 3.94); 0.11 
6 / 242 (2.48%) vs. 8/292 1.07 (0.37. 
(2.74%) 3.05); 0.90 
7 / 182 (3.85%) vs. 8/292 2.09 (0.76- 
(2.74%) 7.81); 0.16 
4 i 242 (1.65%) vs. 11292 4.35 (0.49. 
(0.34%) 38.9): 0.19 
2 / 182 (1.10%) vs. 11292 3.09 (0.28- 
(0.34%) 34.5); 0.36 
13/242 (5.37%) vs. 16/ 0.95 (0.46. 
292 (5.48%) 1 98); 0.90 
17/182 (9.34%) vs. 161 1.59 (0.80. 
292 (5.48%) 3.17); 0.18 
171242 (7.02%) vs. 101 1.67 (0.72. 
292 (3.44%) 3.90); 0.23 
161182 (8.79%) vs. IO/ 2.87 (1.26- 
292 (3.44%) 6.58); 0.01 
57/242 (23.55%) vs. 57/ 1.17 (0.80- 
292 (19.52%) 1.71); 0.42 
34/182 (18.88%) vs. 57/ 0.94 (0.60~ 
292 (19.52%) 1.45); 0.76 
101242 (4.13%) vs. 5/292 2.54 (0.78~ 
(1.71%) 8.42); 0.13 
4 / 182 (2.20%) vs. 5/292 1.29 (0.32- 
(1 71%) 5.29); 0.72 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction 
Dar&z Dudek Jacek Legutko, Stanislaw Barius. Arlur Dziewierz, Krzysztof Zmudka, 
Mieczysfaw Pasowicz, Wieslawa Tracz, Jacek S. Dubiel. Jagiellonian University, 
Krakow, Poland 
Background: Patency of infarct related artery (IRA) before primary percutaneous coro- 
nary intervention (PCI) for acute myocardial infarction (AMI) is associated with better out- 
come. However, there IS no data on the influence of IRA patency before PCI on 
myocardial perfusion and in-hospital outcome of patients (pts) undergoing facilitated PCI. 
Methods: 198 non shock pts with AMI admitted to remote hospitals were enrolled if they 
presented within 12 hrs of chest pain onset. were eligible for thrombolysis and if the 
anticipated transfer time to catheterization laboratory was > 90 min. All pts received i.v. 
bolus of 60Ulkg heparin, 15 mg alteplase and 0.25 mglkg abciximab at the remote hospl- 
tal and were immediately transferred to anglography. Infusion of alteplase (35mg/60 min) 
and abclximab (0.125 uglkglmin) was contmued during transfer. Results: Start of lythic 
therapy to angiography time was 126+51 min. At baseline angiography occluded IRA 
(TIMI 0+1) was found in 14% of pts (group 1) and patent IRA (TIMI 2+3) in 86% of pts. 
(group 2). Immediate PCI was performed I” all patients in group 1, and in 75% of pts in 
group 2. Frequency of TIMI- flow after PCI, myocardlal perfusion grade (MPG-3) after 
PCI and in-hospital MACE (death, re-AMI. re-PCI) for both groups are shown in the 
Table. Conclusions: This combined lythic therapy resulted I” 86% of opened IRA before 
PCI. Patients with occluded IRA at baseline had worse myocardlal perfusion and in-hos- 
pital clinical outcome even after successful PCI. 
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Table 
TIMI before PCI TIMI O+l TIMI 2+3 
n= 27 171 
TIMI 3 after PCI (%) 96.2 92.5 
MPG 3 after PCI (%) 19.1 49.0 
Death (%) 7.4 2.3 
Re-AMI (%) 7.4 0 
PC 
NS 
0.01 
NS 
NS 
Re-PCI (%I 
MACE (%) 
849F0 
3.7 0.6 NS 
18.5 2.9 0.001 
ORAL CONTRIBUTIONS 
Featured Oral Session...Using Risk 
Stratification Tools for Treatment 
Decisions in Patients With Acute 
Coronary Syndromes 
Tuesday, April 01, 2003, 2:00 p.m.-3:30 p.m. 
McCormick Place, Vista S406 A 
2:15 p.m. 
849FO-2 Degree of Baseline Risk Should, But Does Not, 
Influence Treatment Decisions in Non-ST Elevation 
Acute Coronary Syndromes: Evidence From 
international Clinical Trials 
Padma Kaul, L. Kristin Newby. Yuling Fu. Harrington Robert, Christopher Granger, Frans 
J. Van de Wed. Daniel Mark, Paul W. Armstrong, University of Alberta, Edmonton, AB, 
Canada, Duke Clinical Research Institution, Durham, NC 
Background: Increasing ST-segment depression (ST-dep) on the baseline ECG is an 
important tool for risk-stratification in non-ST elevation (NSTE) acute coronary syn- 
dromes (ACS). In particular, the presence of ST-dep identifies patients with the greatest 
ischemic burden most likely to benefit from early invasive therapy. The ACCiAHA Guide- 
fines denote new or presumably new ST-dep a class IA recommendation for early inva- 
sive strategy. However, whether this recommendation is followed in practice is not 
known. 
Methods: We examined temporal and international patterns in the extent to which the 
degree of ST-dep influences the use of angiography, PCI and CABG over a five-year 
time frame (‘94 - ‘99). 
Results: Patients enrolled in GUSTO-Pb (5632) PARAGON-A (1246) and PARAGON-B 
(855) were included. 
Conclusions: Irrespective of region of enrollment, there appears to be ltttle relationship 
between the extent of ST-dep and the use of invasive procedures. These data under- 
score the need for better implementation of guidelines to captitalize on unrealized oppor- 
tunities for more efficient use of angiography and revascularization procedures among 
high risk NSTE ACS patients. 
category 
N 
us 
Angiography 
PC 
CABG 
Canada 
Angiography 
PCI 
CABG 
Europe 
Angiography 
PCI 
CABG 
No ST-dep 
3694 
61 
33 
17 
46 
19 
6 
53 
20 
9 
lmm ST-dep ST-dep>=Zmm 
2619 1420 
60 77 
28 29 
24 33 
49 
15 
15 
51 
19 
11 
40 
12 
14 
50 
16 
16 
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849FO-3 Abciximab Treatment Does Not influence Levels of 
Inflammatory Markers in Patients With Acute Coronary 
Syndrome 
Stefan James, Paul W. Armstrong, Robert M. Califf, Agneta Siegbahn. Maarten 
Simoons, University Hospital, Uppsala, Sweden 
Background: The GUSTO IV trial included 7800 patients with ACS without 
ST-elevation and the patients were not scheduled for early revascularization. 
There was no clinical benefit of abciximab infusion for 24 or 46 hours compared 
to placebo. Through cross-reactivity with other tntegrin receptors, abcedmab 
may influence the inflammation system, which has emerged as one plausible 
explanation for unexpected lack of clinical benefit. 
Methods: In the dalteparin substudy all patients received dalteparin in stead of unfrac- 
tionated heparin. Serial serum samples for analyses of Interleukin-6 (k-6) and high sensi- 
tive C-reactive protein (CRP) were obtained from all patients (11~404) at selected sites. 
Results: 
II-6 @g/L) Placebo 
Abciximab 24 h 
Abciximab 46 h 
P’ 
Baseline 24h 46h 72h 
5.7 7.6 6.1 6.6 
5.2 7.0 6.7 6.1 
5.3 7.9 8.1 6.6 
“.s “.S n.s n.s 
CRP(mg/L) Placebo 4.4 a.4 6.4 7.7 
Abciximab 24 h 4.2 7.0 6.7 6.1 
Abciximab 46 h 4.9 9.2 8.2 9.0 
P n.s n.s n.s n.s 
‘Kruskal-Wallis test 
Conclusion: In patients wtth non-ST elevation ACS levels of inflammatory markers 
raised early. However, the inflammatory activity, as measured by levels of II-6 and CRP, 
was not influenced by abciximab treatment. 
2:45 p.m. 
849FO-4 Suboptimal Adherence to the ACC/AHA Non-ST 
Elevation Acute Coronary Syndrome Practice 
Guidelines for Patients With Positive Troponin Levels 
Matthew T. Roe, Eric D. Peterson, Yun Li, Robert A. Harrington, Charles V. Pollack. 
Ralph G. Brindis, Robert H. Christenson, Sidney C. Smith, Jr., W. Brtan Gibler, E. 
Magnus Ohman, Duke Clinical Research Institute, Durham, NC 
Background: ACC/AHA guidelines for the treatment of non-ST-elevation acute coronary 
syndromes (NSTE ACS) recommend aggressive early management for patrents with 
positive troponin levels, but the influence of troponin results on the quality of care pro- 
vided to ACS patients has not been evaluated. 
Methods: Troponin results were recorded in 16,079 of 16,905 high-risk patients with 
NSTE ACS (ischemic ST-segment changes or positive cardiac markers) in the CRU- 
SADE quality improvement initiative. Troponin results were determined to be positive 
(any value within the first 24 hours > upper limit of normal) in 12,365 of 16,079 (75%) 
patients. Use of acute therapies and interventions given Type IA recommendattons by 
the ACC/AHA guidelines was evaluated in patients without contraindications to the given 
therapies stratified by troponin results. 
Results: The table shows adjusted odds ratios for the Ikkelihood that troponin-positive 
patients received the grven treatment. Conclusions: NSTE ACS patients with positive 
troporiins are managed more aggressively than patients with negative troponins, but type 
IA recommendations from the ACC/AHA guidelines are under-ublized in all patients. 
Increased use of evidence-based therapies for patients with positive troponins may 
reduce the high mortality seen in this group. 
Positive Negative Adjusted 95% Adjusted 
Troponins Troponins Odds Ratio Cl P-Values 
Aspwin < 24 hrs(%) 90.7 88.6 1.42 1.24. <O.OOOl 
1.64 
Clopidogrel c 24 hrs 36.3 32.9 1.36 1.24. <O.OOOl 
(%) 1.49 
Heparin < 24 hrs 85.5 76.9 2.16 1.94 <0.0001 
(%) 2.40 
GP Ilb/llla Inhibitors 33.6 22.7 2.16 1.95. <0.0001 
< 24 hrs (%) 2.40 
Early Cardiac Cath 44.2 40.3 1.54 1.40 ~0.0001 
< 46 hrs (%) 1.70 
In-Hospital Mortality 5.9 2.6 1.76 1.36. c0.0001 
(%) 2.26 
